The Principal Investigator's (PI) working hypothesis is that the PI can utilize the high
predictive value of 18F-DCFPyl PSMA to identify clinically significant tumors in patients who
will undergo brachytherapy, as well as areas which are uninvolved or contain only clinically
insignificant disease.
In the PI's clinical trial, the uninvolved regions (as defined by combined PET-MR-biopsy
data) will not be targeted and receive only fall-off dose, which we have shown to be
associated with reductions in toxicity.
Phase:
Early Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators:
National Cancer Institute (NCI) National Institutes of Health (NIH)